Moonlight Therapeutics is a pre-clinical stage allergen immunotherapy company developing treatments for food allergies. Moonlight’s platform uses a proprietary skin stamp that allows targeted delivery of therapeutics to the immune system. Our initial therapy is designed to desensitize children suffering from a peanut allergy (over 1.5 million in the USA). We are raising our first equity/ Series A round of $5 million to fund the first human clinical trial in peanut allergic individuals. We’ve completed a pre-IND meeting with the FDA, completed IND enabling non-clinical studies, and expect to submit our IND in 2022. We’ve received a notice of allowance from the USPTO on a patent for treating peanut allergies.